Kimberly-Clark is an overlooked Dividend King with a 54-year consecutive dividend increase streak matching PepsiCo's. Despite lower brand recognition, KMB offers a higher yield (4.7% vs 4.1%), more resilient demand for household products, and is acquiring Kenvue to enhance its global portfolio, making it an attractive option for income-focused investors.

Johnson & Johnson and AbbVie are recommended as long-term dividend stocks to hold indefinitely. Both are Dividend Kings with strong cash flows, reliable dividend payments, and solid historical returns. JNJ has increased dividends for 64 consecutive years with a 1.96% yield, while ABBV has 54 years of increases with a higher 2.6% yield and stronger recent performance.

Johnson & Johnson is transitioning from a slow-growth dividend stock into a growth machine, driven primarily by its oncology business. The company's cancer drugs, particularly Darzalex, are growing at high-teen rates, positioning J&J to achieve its goal of $50 billion in annual cancer drug sales by 2030. With the global cancer treatment market expected to grow at 11.3% annually through 2035, J&J is well-positioned to capture significant market share despite being primarily viewed as an income investment.

Johnson & Johnson delivered strong earnings with revenue growth of 6% to $25 billion and raised full-year guidance to $101.1 billion. Key drugs like Darzalex (up 18%) and Tremfya (up 72%) offset Stelara declines. While the stock has gained 22% this year and trades near valuation highs, the company's broad portfolio of 28+ blockbuster products and 50+ years of dividend increases make it attractive for long-term and dividend-focused investors, though value investors may wait for a better entry point.

Ken Griffin increased his stake in Johnson & Johnson by 146% in Q1 2026, bringing his total holdings to nearly 2 million shares. The article highlights J&J as an ideal stock for risk-averse investors due to its diversified portfolio of 28+ billion-dollar products, strong revenue growth in pharmaceuticals and medtech following the Kenvue spinoff, and its status as a Dividend King with 50+ consecutive years of dividend increases and a 2% yield.

The article compares Church & Dwight and Kimberly-Clark as investment options in the consumer goods sector. Church & Dwight operates a lean portfolio of power brands with a strong balance sheet (0.6x debt-to-equity), while Kimberly-Clark is a larger global player undergoing transformation with higher leverage (4.9x debt-to-equity). The author recommends Church & Dwight for investors seeking a balance of growth and dividend income, citing its stronger financial position and focused strategy, despite Kimberly-Clark's larger scale and higher dividend yield.

Kimberly-Clark is outperforming the S&P 500 and Nasdaq in 2026 with a 4.5% dividend yield and 54 consecutive years of dividend increases. The company trades at a discount valuation (15.2x 2026 earnings vs. 21.9x historical median) and is acquiring Kenvue to diversify revenue streams and unlock $2.1 billion in annual synergies. However, risks include execution challenges from the acquisition and potential dividend sustainability concerns.

Colgate-Palmolive has surged 20.4% year-to-date and stands out as a Dividend King with 63 consecutive years of dividend increases. Despite industry headwinds from inflation and consumer resistance to price increases, the company has demonstrated resilience through its elite brand portfolio, efficient operations, and strong geographic diversification. Trading at 25x forward earnings with a 2.2% dividend yield, the stock is positioned to continue outperforming broader market indexes in the second half of 2026.

The article recommends three healthcare stocks for long-term buy-and-hold portfolios: Johnson & Johnson, Abbott Laboratories, and UnitedHealth Group. All three are praised for their stable dividends, strong cash flows, economic moats, and ability to weather economic downturns. Johnson & Johnson and Abbott are Dividend Kings with 64 and 54 consecutive years of dividend increases respectively, while UnitedHealth Group benefits from its dual-engine model combining insurance and healthcare delivery.

The article recommends three dividend stocks for long-term 10-year investors: Clorox (strengthened by its Purell acquisition and offering a 5% yield), Brown-Forman (with 42 consecutive years of dividend increases and a 3.6% yield despite current market softness), and Kimberly-Clark (undergoing major transformation with trusted brands and 50+ years of dividend growth). All three are positioned as overlooked opportunities for patient investors seeking steady compounding returns.

In an uncertain market marked by tariff-driven inflation and low consumer sentiment, the article recommends three consumer staples companies as stable investments for a $1,000 allocation: Church & Dwight for its volume-driven growth, Keurig Dr Pepper for its high-growth energy drink portfolio, and Kenvue for its strong beauty and health brands ahead of its merger with Kimberly-Clark.

The article compares Kimberly-Clark and Clorox as investment options for 2026. Both companies face challenges including high debt loads, customer concentration risk (Walmart accounts for 16-27% of sales), and intense competition. Kimberly-Clark is undergoing significant restructuring with a potential $48 billion merger with Kenvue and selling its international tissue business, while Clorox is recovering from a 2023 cyberattack and pandemic-era slowdown. The author recommends Clorox as the safer choice due to its stronger brand positioning, though acknowledges Kimberly-Clark offers higher upside potential despite greater integration risks.